Adrian Rawcliffe
2020
In 2020, Adrian Rawcliffe earned a total compensation of $2.7M as Chief Executive Officer at Adaptimmune Therapeutics, a 26% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $378,840 |
|---|---|
| Option Awards | $1,715,346 |
| Salary | $574,000 |
| Other | $33,416 |
| Total | $2,701,602 |
Rawcliffe received $1.7M in option awards, accounting for 63% of the total pay in 2020.
Rawcliffe also received $378.8K in non-equity incentive plan, $574K in salary and $33.4K in other compensation.
Rankings
In 2020, Adrian Rawcliffe's compensation ranked 4,250th out of 13,090 executives tracked by ExecPay. In other words, Rawcliffe earned more than 67.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,250 out of 13,090 | 68th |
Division Manufacturing | 1,716 out of 5,624 | 70th |
Major group Chemicals And Allied Products | 666 out of 2,257 | 71st |
Industry group Drugs | 569 out of 1,957 | 71st |
Industry Biological Products, Except Diagnostic Substances | 130 out of 411 | 68th |
Source: SEC filing on April 21, 2022.
Rawcliffe's colleagues
We found four more compensation records of executives who worked with Adrian Rawcliffe at Adaptimmune Therapeutics in 2020.